Deseret News (Salt Lake City) - Correction: Actiq
May 19, 2004 -- The prescription painkiller Actiq acts on the body's opiate receptors in a way similar to opium, but it is derived from a synthetic compound called...
Deseret News (Salt Lake City) - Use and abuse of Actiq surging
May 18, 2004 -- In the wake of the controversy over the prescription narcotic Oxycontin, health experts and insurers are raising concerns about the increasing use --...
Chain Drug Review - Generic versions of Actiq, Balziva introduced by Barr
October 23, 2006 -- WOODCLIFF LAKE, N.J. -- Barr Pharmaceuticals Inc. has launched a generic version of Actiq, a cancer pain management product. In addition, the...
Chain Drug Review - Pennsylvania officials cite abuse of Actiq
May 24, 2004 -- Pennsylvania officials report that Actiq, a berry-flavor lozenge on a stick like a lollipop, is emerging in illegal sales under the nickname...
Deseret News (Salt Lake City) - FDA says Cephalon's Actiq product is 'approvable'
March 26, 2005 -- FRAZER, Pa. (Dow Jones/AP) -- Cephalon Inc. Friday said the U.S. Food and Drug Administration considers the new, sugar-free formulation of pain drug...
Chain Drug Review - Sugar-free Actiq O.K.'d
September 26, 2005 -- Cephlon Inc. has received FDA approval to market a sugar-free formulation of Actiq. The company hopes to launch the medicated lozenge, for the...
Deseret News (Salt Lake City) - Cephalon gets OK to market sugar-free form of Actiq drug
September 13, 2005 -- Pennsylvania-based Cephalon Inc., which has a manufacturing facility in Salt Lake City, has received U.S. Food and Drug Administration approval to...
Deseret News (Salt Lake City) - Cephalon seeking OK for its sugar-free Actiq
December 2, 2004 -- Pennsylvania-based Cephalon Inc., which makes its cancer-pain- relieving drug Actiq in Salt Lake City, said Wednesday it has filed with federal...
Deseret News (Salt Lake City) - Firm moves manufacturing of drug Actiq to S.L. facility
April 3, 2003 -- Pennsylvania-based Cephalon Inc. said Wednesday it has moved manufacturing of its Actiq drug for the U.S. market to Salt Lake City. The move is...
Business Wire - Elan Sells Its Actiq Rights to Cephalon for $50 Million in Cash
October 3, 2002 -- Business Editors & Health/Medical Writers DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 3, 2002 Elan Corporation, plc (NYSE: ELN) ("Elan") today...
